Similis Bio has signed its first development and license agreement with Brazilian pharmaceutical firm Blau Farmaceutica.
Over the next several years, the partnership will develop four biosimilar assets. These drugs have a global market value of...
Similis Bio And Blau To Co-Develop Four Biosimilars For The Americas
The Drugs Have An Estimated Global Market Value Of $42bn
Listen to this article
JSR Life Science’s new business unit embarks on its first partnership with publicly listed Brazilian pharmaceutical.
Stay ahead of every shift in generics and biosimilars.
More from Deals
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
More from Business
• By
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
• By
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.